Einfach Bitcoin kaufen: Mit dem Code "FINANZEN" sparen Sie 21% der Gebühren für 6 Monate bei Coinfinity. Jetzt loslegen -w-
10.06.2014 14:28:31

Northwest Bio Initiates Phase III DCVax-L Trial In Germany - Quick Facts

(RTTNews) - Northwest Biotherapeutics (NWBOW, NWBO, NWBS.L) announced it has initiated the Phase III trial of DCVax-L in Germany. The company said the first German site is now starting to screen patients for purposes of enrollment. The company has scheduled the full-day site initiations for 3 more sites during June and 4 further sites in July.

Linda Powers, CEO of NW Bio, said: "We are excited to have the Phase III DCVax-L trial open for enrollment in Germany. It has taken a major team effort to accomplish the steps required for these sites. However, we are now ready to initiate a substantial set of clinical trial sites throughout Germany, and we have built a strong foundation for our clinical programs in Germany."

The trial has been enrolling in parallel in the US and Europe (in the UK), as previously announced, the company noted.

Nachrichten zu Northwest Biotherapeutics Incmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Northwest Biotherapeutics Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Northwest Biotherapeutics Inc 0,27 -6,90% Northwest Biotherapeutics Inc